ArticleThe British journal of radiology2020
Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer.
Article in The British journal of radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Economic Evaluations of Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Article
- Practice development perspective of RTT contouring in online adaptive radiotherapy for prostate cancer: A single-centre cost-consequence analysis.Technical innovations & patient support in radiation oncology · 2026Article
- Exploratory health economic analyses to support decisions within the innovation process in radiotherapy: Magnetic Resonance Linear Accelerator as a case study.Technical innovations & patient support in radiation oncology · 2025Article
- Treatment time and learning curve analysis of 1.5 T MR-Linac workflows led by radiation oncologists or therapists.Clinical and translational radiation oncology · 2025Article
- Economic Evaluation of a Novel MicroRNA-Based Assay to Determine Risk of Late Genitourinary Radiation Toxicity in Patients With Prostate Cancer.Journal of health economics and outcomes research · 2025Article
- MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study.Clinical and translational radiation oncology · 2024Article
- MRI-Guided Radiation Therapy for Prostate Cancer: The Next Frontier in Ultrahypofractionation.Cancers · 2023Review
- Adaptive radiotherapy for breast cancer.Clinical and translational radiation oncology · 2023Review
- Review
- Integrated MRI-guided radiotherapy - opportunities and challenges.Nature reviews. Clinical oncology · 2022Review
- Assessment of MRI-Linac Economics under the RO-APM.Journal of clinical medicine · 2021Article
- Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT.Applied radiation oncology · 2021Article
- Implications of Radiotherapy Utilization in Korea from 2010 to 2019.Journal of Korean medical science · 2021Article
- MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo determine the toxicity reduction required to justify the added costs of MRI-guided radiotherapy (MR-IGRT) over CT-based image guided radiotherapy (CT-IGRT) for the treatment of localized prostate cancer.
methodsThe costs of delivering prostate cancer radiotherapy with MR-IGRT and CT-IGRT in conventional 39 fractions and stereotactic body radiotherapy (SBRT) 5 fractions schedules were determined using literature values and cost accounting from two institutions. Gastrointestinal and genitourinary toxicity rates associated with CT-IGRT were summarized from 20 studies. Toxicity-related costs and utilities were obtained from literature values and cost databases. Markov modeling was used to determine the savings per patient for every 1% relative reduction in acute and chronic toxicities by MR-IGRT over 15 years. The costs and quality adjusted life years (QALYs) saved with toxicity reduction were juxtaposed with the cost increase of MR-IGRT to determine toxicity reduction thresholds for cost-effectiveness. One way sensitivity analyses were performed. Standard $100,000 and $50,000 per QALY ratios were used.
resultsThe added cost of MR-IGRT was $1,459 per course of SBRT and $10,129 per course of conventionally fractionated radiotherapy. Relative toxicity reductions of 7 and 14% are required for SBRT to be cost-effective using $100,000 and $50,000 per QALY, respectively. Conventional radiotherapy requires relative toxicity reductions of 50 and 94% to be cost-effective.
conclusionFrom a healthcare perspective, MR-IGRT can reasonably be expected to be cost-effective. Hypofractionated schedules, such a five fraction SBRT, are most likely to be cost-effective as they require only slight reductions in toxicity (7-14%). ADVANCES IN KNOWLEDGE: This is the first detailed economic assessment of MR-IGRT, and it suggests that MR-IGRT can be cost-effective for prostate cancer treatment through toxicity reduction alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.